Presenting clinical data of
REOLYSIN® in metastatic
breast cancer
and the Company's strategic objectives
CALGARY and SAN DIEGO, Oct. 11,
2017 /PRNewswire/ - Oncolytics Biotech® Inc.
(TSX: ONC) (OTCQX: ONCYF), a biotech company developing
REOLYSIN®, a first-in-class, intravenously delivered
immuno-oncolytic virus that activates the innate and adaptive
immune systems, today announced that Matt
Coffey, Ph.D., President & Chief Executive Officer, will
present a corporate overview and outline strategic objectives at
the 2017 BIO Investor Forum.
2017 BIO Investor Forum
Presenter: Matt Coffey, Ph.D.,
President & Chief Executive Officer, Oncolytics Biotech
Presentation Date and Time: Wednesday,
Oct. 18, 2017, 10:00:00 a.m.
PT
Location: Westin St. Francis Hotel, Elizabethan C, San Francisco
Dr. Coffey will provide a company overview and highlight recent
progress, including randomized phase 2 data in metastatic breast
cancer demonstrating a statistically significant increase in
overall survival. This progress lead to receiving fast-track
designation and conducting a successful End-of-Phase 2 Meeting with
the U.S. Food and Drug Administration (FDA), resulting in plans for
a single 400-patient phase 3 registration study, the impetus to
advance global and/or regional partnership conversations and the
objective of relisting on NASDAQ in 2018.
Supported by a fast-track designation, Oncolytics is preparing
the most appropriate development path to obtain regulatory approval
for REOLYSIN for metastatic breast cancer, an indication with
continued and considerable unmet need. In September, the Company
announced a successful End-of-Phase 2 Meeting with the FDA for
REOLYSIN in combination with paclitaxel, for the treatment of
hormone receptor positive, HER2 receptor negative (HR+/HER2-)
metastatic breast cancer patients. The purpose of the meeting
included a discussion of the design of a phase 3 registration study
to support a future Biologics License Application (BLA) submission
in the U.S.
Oncolytics is pursuing additional immunomodulatory and/or check
point inhibitor combinations in collaboration with pharmaceutical
companies to further explore the mechanism of action and potential
new treatment applications and additional market opportunities. In
September, the first patient was treated in the Company's Phase 1b
trial run by Myeloma UK (MUK) called MUK eleven, studying REOLYSIN
in combination with Celgene Corporation's immunomodulatory drugs,
Revlimid® or Imnovid® as a rescue treatment
in relapsing myeloma patients.
A live audio link to the webcast session will be available on
the Company's website at
http://www.oncolyticsbiotech.com/investor-centre/presentations. It
is recommended that listeners log on 10 minutes in advance of a
live session to register and download any necessary software. An
audio replay will be accessible approximately two hours following
the presentation on the Oncolytics website.
About BIO Investor Forum
BIO Investor Forum is an
international biotech investor conference focused on early and
established private companies as well as emerging public companies.
The event features plenary sessions, business roundtables and
therapeutic workshops, company presentations, and One-on-One
Partnering™ meetings.
About Oncolytics Biotech Inc.
Oncolytics is a
biotechnology company developing REOLYSIN, an intravenously
delivered immuno-oncolytic virus. The compound induces selective
tumor lysis and promotes an inflamed tumor phenotype through innate
and adaptive immune responses to treat a variety of cancers.
Oncolytics' clinical development program emphasizes three pillars:
chemotherapy combinations to trigger selective tumor lysis;
immuno-therapy combinations to produce adaptive immune responses;
and immune modulator (IMiD) combinations to facilitate innate
immune responses. Oncolytics is currently planning its first
registration study in metastatic breast cancer, as well as studies
in combination with checkpoint inhibitors as well as targeted and
IMiD therapies in solid and hematological malignancies. For
further information about Oncolytics, please
visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements,
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements, including the
Company's belief as to the potential of REOLYSIN® as a
cancer therapeutic; the Company's expectations as to the success of
its research and development programs in 2017 and beyond, the
Company's planned operations, the value of the additional patents
and intellectual property; the Company's expectations related to
the applications of the patented technology; the Company's
expectations as to adequacy of its existing capital resources; the
design, timing, success of planned clinical trial programs; and
other statements related to anticipated developments in the
Company's business and technologies involve known and unknown risks
and uncertainties, which could cause the Company's actual results
to differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN as a cancer
treatment, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize
REOLYSIN, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should
consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance
on forward-looking statements. The Company does not undertake to
update these forward-looking statements, except as required by
applicable laws.
SOURCE Oncolytics Biotech Inc.